In yesterday’s Wall Street session, Hims & Hers Health Inc (NYSE:HIMS) shares traded at $49.85, up 0.89% from the previous session.
HIMS stock price is now 1.16% away from the 50-day moving average and 45.53% away from the 200-day moving average. The market capitalization of the company currently stands at $11.16B.
On June 04, 2025, Needham reiterated its ‘Buy’ rating on the stock by increasing its target price from $61 to quote $65, while ‘TD Cowen’ rates the stock as ‘Hold’
In other news, Boughton Soleil, Officer bought 2,572 shares of the company’s stock on Jun 30 ’25. The stock was bought for $129,886 at an average price of $50.50. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23 ’25, Chief Financial Officer Okupe Oluyemi sold 23,107 shares of the business’s stock. A total of $1,091,766 was realized by selling the stock at an average price of $47.25. This leaves the insider owning 63,222 shares of the company worth $3.15 million. A total of 14.80% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $13.47 and a high of $72.98. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 1.59, and a quick ratio of 1.32. According to the stock market information, the enterprise value for the company is $10898714624, which is based on a 72.56 price-to-earnings ratio, a 2.10 price-to-earnings-growth ratio, and a beta of 2.04. The fifty day moving average price for HIMS is $49.2768 and a two-hundred day moving average price translates $34.25475 for the stock.
The latest earnings results from Hims & Hers Health Inc (NYSE: HIMS) was released for 2025-03-31. The net profit margin was 9.21% and return on equity was 36.79% for HIMS. The company reported revenue of $586.01 million for the quarter, compared to $278.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 110.67 percent.
